The FDA granted accelerated approval to dostarlimab-gxly for adults with mismatch repair-deficient recurrent or advanced solid tumors that progressed on or after prior treatment and who have no ...

Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of 20 ...

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in ...

Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image–Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study The College of American ...

Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch repair-deficient tumors. The rate of grade 3 or greater adverse events was slightly higher ...

Among patients with mismatch repair–deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this ...

A retrospective study found that patients with mismatch repair (MMR)-deficient advanced or recurrent endometrial cancer had numerically longer overall survival (OS) than those with MMR-proficient ...

The US Food and Drug Administration has approved a DNA mismatch repair (MMR) companion test to identify patients suitable for treatment with Merck's pembrolizumab (Keytruda). The Ventana MMR RxDx ...

15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) We conducted a prospective, multicenter ...

A widely-circulated clinical trial published earlier this year in the New England Journal of Medicine described a new treatment that eradicated cancer in all 12 of its patients with locally advanced ...